Start of Dicot's phase 1 trial booked for August
Press release: Uppsala, May 2, 2023. Dicot's development of its potency drug candidate LIB-01 is proceeding according to plan and the company has now scheduled the start of its phase 1 trial for August 2023 at CTC AB who will conduct the study.
Dicot is developing a new potency drug that aims to become the first choice of treatment for erectile dysfunction and premature ejaculation. The company has previously announced that it intends to start clinical phase 1 trial on the drug candidate LIB-01 in mid-2023. To ensure a start according to plan, the company has now reserved capacity at the contracted research clinic and the start date is set for August 2023. The reputable CTC AB in Uppsala will conduct the study. The start in August must be preceded by Dicot submitting the necessary documents to the Swedish Medical Products Agency and receiving permission to start the study.
"We have consistently fulfilled our duties in Dicot's development plan and have now come so far in the preparations for phase 1 that we feel confident in setting a date for clinical start," says Charlotta Gauffin, Dicot´s CSO.
For further information, please contact:
Elin Trampe, CEO
Phone: +46 739 80 14 08
E-mail: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 4,100 shareholders. For more information, please visit www.dicot.se.